Remegen Receives Clinical Trial Approval for Bispecific ADC Drug RC288

Stock News04-01 16:50

Remegen Co., Ltd. (688331.SH) announced that it has received a clinical trial approval notice from the National Medical Products Administration. The approval permits the company to proceed with a Phase I/IIa clinical trial of its self-developed bispecific antibody-drug conjugate (ADC) RC288 as a monotherapy for locally advanced unresectable or metastatic malignant solid tumors. RC288 is a bispecific ADC that targets both PSMA and B7H3. It is an innovative drug molecule developed by Remegen using next-generation conjugation and toxin technology. PSMA, or prostate-specific membrane antigen, is a type II transmembrane glycoprotein that supports tumor growth and angiogenesis. B7H3 is an immune checkpoint molecule that, when overexpressed in tumors, promotes immune evasion and tumor progression. Both PSMA and B7H3 are considered promising therapeutic targets, as they are highly expressed in various malignant tumor tissues and tumor neovascularure and are involved in signaling pathways related to tumor proliferation, invasion, and drug resistance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1194246479?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 16:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194246479","market":"sg","top_or_hot":-1,"title":"Remegen Receives Clinical Trial Approval for Bispecific ADC Drug RC288","media":"Stock News","content":"<p>Remegen Co., Ltd. (688331.SH) announced that it has received a clinical trial approval notice from the National Medical Products Administration. The approval permits the company to proceed with a Phase I/IIa clinical trial of its self-developed bispecific antibody-drug conjugate (ADC) RC288 as a monotherapy for locally advanced unresectable or metastatic malignant solid tumors. RC288 is a bispecific ADC that targets both PSMA and B7H3. It is an innovative drug molecule developed by Remegen using next-generation conjugation and toxin technology. PSMA, or prostate-specific membrane antigen, is a type II transmembrane glycoprotein that supports tumor growth and angiogenesis. B7H3 is an immune checkpoint molecule that, when overexpressed in tumors, promotes immune evasion and tumor progression. Both PSMA and B7H3 are considered promising therapeutic targets, as they are highly expressed in various malignant tumor tissues and tumor neovascularure and are involved in signaling pathways related to tumor proliferation, invasion, and drug resistance.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Remegen Receives Clinical Trial Approval for Bispecific ADC Drug RC288</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRemegen Receives Clinical Trial Approval for Bispecific ADC Drug RC288\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-01 16:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Remegen Co., Ltd. (688331.SH) announced that it has received a clinical trial approval notice from the National Medical Products Administration. The approval permits the company to proceed with a Phase I/IIa clinical trial of its self-developed bispecific antibody-drug conjugate (ADC) RC288 as a monotherapy for locally advanced unresectable or metastatic malignant solid tumors. RC288 is a bispecific ADC that targets both PSMA and B7H3. It is an innovative drug molecule developed by Remegen using next-generation conjugation and toxin technology. PSMA, or prostate-specific membrane antigen, is a type II transmembrane glycoprotein that supports tumor growth and angiogenesis. B7H3 is an immune checkpoint molecule that, when overexpressed in tumors, promotes immune evasion and tumor progression. Both PSMA and B7H3 are considered promising therapeutic targets, as they are highly expressed in various malignant tumor tissues and tumor neovascularure and are involved in signaling pathways related to tumor proliferation, invasion, and drug resistance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1194246479","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194246479","pubTimestamp":1775033435,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Remegen Co., Ltd. (688331.SH) announced that it has received a clinical trial approval notice from the National Medical Products Administration. The approval permits the company to proceed with a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688331":"荣昌生物","09995":"荣昌生物","BK1161":"生物科技","BK1574":"生物医药B类股","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1583":"高瓴概念","ADC":"艾格里房产","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0239":"医药制造","BK4231":"零售房地产信托","BK4080":"零售业房地产投资信托"},"translate_title":"Remegen双特异性ADC药物RC288获临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688331":1,"ADC":1,"09995":1},"content_text":"Remegen Co., Ltd. (688331.SH) announced that it has received a clinical trial approval notice from the National Medical Products Administration. The approval permits the company to proceed with a Phase I/IIa clinical trial of its self-developed bispecific antibody-drug conjugate (ADC) RC288 as a monotherapy for locally advanced unresectable or metastatic malignant solid tumors. RC288 is a bispecific ADC that targets both PSMA and B7H3. It is an innovative drug molecule developed by Remegen using next-generation conjugation and toxin technology. PSMA, or prostate-specific membrane antigen, is a type II transmembrane glycoprotein that supports tumor growth and angiogenesis. B7H3 is an immune checkpoint molecule that, when overexpressed in tumors, promotes immune evasion and tumor progression. Both PSMA and B7H3 are considered promising therapeutic targets, as they are highly expressed in various malignant tumor tissues and tumor neovascularure and are involved in signaling pathways related to tumor proliferation, invasion, and drug resistance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1194246479","isCrawlerRequest":true}